Sun Pharma Shines Bright: FY26 Investor Presentation Reveals Rs 582 Bn Sales & ‘Best-in-Class’ Profitability
Sun Pharmaceutical Industries Limited has released its latest investor presentation for FY26, highlighting another year of strong financial performance, operational efficiency, and continued global expansion. The company reported robust revenue growth, industry-leading profitability, and a diversified business portfolio that continues to strengthen its position as one of the world’s largest pharmaceutical companies.
With operations spanning more than 100 countries, Sun Pharma remains focused on innovation, specialty medicines, branded generics, and sustainable long-term growth.
Strong Financial Performance in FY26
For the financial year ended March 31, 2026, Sun Pharma reported total sales of ₹582 billion, reflecting the strength of its diversified product portfolio and broad geographic presence.
The company also maintained healthy profitability, supported by operational efficiency and a balanced business mix.
Key FY26 Financial Highlights
- Total Sales: ₹582 billion
- EBITDA Margin: 30.3%
- Adjusted Net Profit Margin: 21.2%
- Return on Capital Employed (ROCE): 20.7%
- Return on Equity (ROE): 17.4%
These figures highlight the company’s ability to generate strong earnings while maintaining efficient capital utilization.
Diversified Global Business Model
Sun Pharma continues to benefit from a geographically diversified revenue base.
According to the investor presentation, the company’s FY26 revenue mix includes:
- India: 33%
- United States: 29%
- Emerging Markets: 19%
- Other Global Markets: Remaining contribution
This balanced revenue distribution helps reduce dependence on any single market while supporting long-term business stability.
Global Manufacturing and Research Capabilities
Sun Pharma has built one of the largest pharmaceutical manufacturing networks among Indian drug makers.
The company currently operates 40 manufacturing facilities worldwide and employs more than 47,000 people across its global operations.
Its business portfolio includes:
- Specialty medicines
- Branded generic formulations
- Generic pharmaceuticals
- Active Pharmaceutical Ingredients (APIs)
The company also continues to invest in research and development, product innovation, and regulatory compliance to strengthen its global competitiveness.
Focus on Long-Term Value Creation
Sun Pharma’s long-term strategy remains centered on expanding its specialty business, enhancing operational excellence, and delivering sustainable growth.
Its diversified business model, strong balance sheet, and global presence position the company to capitalize on growing healthcare demand across developed and emerging markets.